Pharmacokinetic analysis of 6-O-[18F]FEE for PET imaging of EGFR mutation
- 6 March 2023
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 85, 129217
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?European Journal of Cancer, 2017
- Liquid Biopsies, What We Do Not Know (Yet)Cancer Cell, 2017
- Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases ActivityClinical Cancer Research, 2016
- Effects of erlotinib therapy on [11C]erlotinib uptake in EGFR mutated, advanced NSCLCEJNMMI Research, 2016
- Quantitative and Simplified Analysis of 11C-Erlotinib StudiesJournal of Nuclear Medicine, 2016
- Breast Cancer Resistance Protein and P-Glycoprotein Influence In Vivo Disposition of 11C-ErlotinibJournal of Nuclear Medicine, 2015
- A Fully Automated Radiosynthesis of [18F]Fluoroethyl-Diprenorphine on a Single Module by Use of SPE Cartridges for Preparation of High Quality 2-[18F]Fluoroethyl TosylateMolecules, 2013
- Molecular Imaging with11C-PD153035 PET/CT Predicts Survival in Non–Small Cell Lung Cancer Treated with EGFR-TKI: A Pilot StudyJournal of Nuclear Medicine, 2011
- Positron Emission Tomography (PET) Imaging with [11C]-Labeled Erlotinib: A Micro-PET Study on Mice with Lung Tumor XenograftsCancer Research, 2009
- Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline InhibitorJournal of Biological Chemistry, 2002